Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: August 18, 2017
What is the competitive landscape for NOVARTIS PHARMS CORP, and when can generic versions of NOVARTIS PHARMS CORP drugs launch?
NOVARTIS PHARMS CORP has sixty-eight approved drugs.| Patents: | 118 |
| Tradenames: | 58 |
| Ingredients: | 49 |
| NDAs: | 68 |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis Pharms Corp | PROMACTA | eltrombopag olamine | TABLET;ORAL | 022291-004 | Oct 20, 2011 | RX | Yes | No | ► Subscribe | ► Subscribe | Y | ► Subscribe | |||||||||||||||||
Novartis Pharms Corp | PROMACTA | eltrombopag olamine | TABLET;ORAL | 022291-004 | Oct 20, 2011 | RX | Yes | No | ► Subscribe | ► Subscribe | Y | ► Subscribe | |||||||||||||||||
Novartis Pharms Corp | FLUORESCITE | fluorescein sodium | INJECTABLE;INTRAVENOUS | 021980-001 | Mar 28, 2006 | AP | RX | Yes | Yes | ► Subscribe | ► Subscribe | ► Subscribe | |||||||||||||||||
Novartis Pharms Corp | MEKINIST | trametinib dimethyl sulfoxide | TABLET;ORAL | 204114-003 | May 29, 2013 | RX | Yes | Yes | ► Subscribe | ► Subscribe | Y | ► Subscribe | |||||||||||||||||
Novartis Pharms Corp | ZOFRAN | ondansetron hydrochloride | INJECTABLE;INJECTION | 020007-001 | Jan 4, 1991 | DISCN | Yes | No | ► Subscribe | ► Subscribe | ► Subscribe | ||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis Pharms Corp | ZOFRAN PRESERVATIVE FREE | ondansetron hydrochloride | INJECTABLE;INJECTION | 020007-003 | Dec 10, 1993 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Novartis Pharms Corp | ZOFRAN | ondansetron hydrochloride | TABLET;ORAL | 020103-002 | Dec 31, 1992 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Novartis Pharms Corp | ZOFRAN ODT | ondansetron | TABLET, ORALLY DISINTEGRATING;ORAL | 020781-002 | Jan 27, 1999 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Novartis Pharms Corp | HYCAMTIN | topotecan hydrochloride | CAPSULE;ORAL | 020981-002 | Oct 11, 2007 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-002 | Mar 30, 2015 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
travoprost | Ophthalmic Solution | 0.003% | IZBA | 12/30/2015 |
nepafenac | Ophthalmic Suspension | 0.3% | ILEVRO | 12/21/2015 |
deferasirox | Tablets | 180 mg | JADENU | 10/23/2015 |
deferasirox | Tablets | 90 mg and 360 mg | JADENU | 10/19/2015 |
olopatadine hydrochloride | Ophthalmic Solution | 0.7% | PAZEO | 9/10/2015 |
difluprednate | Ophthalmic Emulsion | 0.05% | DUREZOL | 5/1/2014 |
eltrombopag olamine | Tablets | 12.5 mg and 25 mg | PROMACTA | 2/4/2014 |
eltrombopag olamine | Tablets | 50 mg and 75 mg | PROMACTA | 1/7/2014 |
ciprofloxacin and dexamethasone | Otic Suspension | 0.3%/0.1% | CIPRODEX | 7/31/2012 |
moxifloxacin hydrochloride | Ophthalmic Solution | 10.5% | MOXEZA | 2/29/2012 |
argatroban in sodium chloride | Injection | 1 mg/mL, 50 mL vials | ARGATROBAN | 12/16/2011 |
lapatinib ditosylate | Tablets | 250 mg | TYKERB | 3/14/2011 |
olopatadine hydrochloride | Nasal Spray | 0.665 mg/ Spray | PATANASE | 6/29/2009 |
travoprost (preserved) | Ophthalmic Solution | 0.00% | TRAVATAN Z | 2/19/2009 |
olopatadine hydrochloride | Ophthalmic Solution | 0.20% | PATADAY | 9/8/2008 |
argatroban | Injection | 100 mg/mL, 2.5 mL vials | ARGATROBAN | 9/24/2007 |
olopatadine hydrochloride | Ophthalmic Solution | 0.10% | PATANOL | 7/17/2006 |
moxifloxacin hydrochloride | Ophthalmic | 0.50% | VIGAMOX | 12/22/2005 |
ondansetron hydrochloride | Oral Solution | 4 mg/5 mL | ZOFRAN | 12/20/2004 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8,445,479 | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity | ► Subscribe | |||||||||||||||||||||||||||
| 6,583,124 | Ophthalmic compositions containing galactomannan polymers and borate | ► Subscribe | |||||||||||||||||||||||||||
| 7,709,012 | Ophthalmic compositions containing a synergistic combination of two polymers | ► Subscribe | |||||||||||||||||||||||||||
| 7,589,200 | 5-Fluoro-4N-phenyl-4-pyrimidineamine compounds | ► Subscribe | |||||||||||||||||||||||||||
| 8,952,018 | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hong Kong | 1156625 | ► Subscribe | |||||||||||||||||||||||||||
| Israel | 127212 | ► Subscribe | |||||||||||||||||||||||||||
| Australia | 2011326620 | ► Subscribe | |||||||||||||||||||||||||||
| Norway | 2016014 | ► Subscribe | |||||||||||||||||||||||||||
| European Patent Office | 2638030 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0140036 00120 | Estonia | ► Subscribe | PRODUCT NAME: TRAMETINIIB;REG NO/DATE: EU/1/14/931 02.07.2014 | ||||||||||||||||||||||||||
| 00683 | Netherlands | ► Subscribe | PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225 | ||||||||||||||||||||||||||
| C/GB03/004 | United Kingdom | ► Subscribe | PRODUCT NAME: BRINZOLAMIDE; REGISTERED: CH IKS 55236 19991217; UK EU/1/00/129/01 20000309; UK EU/1/00/129/02 20000309 | ||||||||||||||||||||||||||
| 90020-1 | Sweden | ► Subscribe | PRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123 | ||||||||||||||||||||||||||
| 2015 00047 | Denmark | ► Subscribe | PRODUCT NAME: CERITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/15/999 (C(2015)3218) 20150506 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,352 others who get our Drug Patent Expiration Alerts:
